Loading...
Market
What will be the market share of Novavax's updated COVID-19 vaccine for JN.1 strain in the US by Mar 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from health agencies and market research firms
Story
FDA Authorizes Novavax's Updated COVID-19 Vaccine for JN.1 Strain, Age 12 and Older
Aug 30, 2024, 06:51 PM
The U.S. Food and Drug Administration (FDA) has authorized an updated version of the Novavax COVID-19 vaccine for emergency use. This updated 2024-2025 Formula vaccine targets the currently circulating variants, specifically the JN.1 strain, and is intended to provide better protection against serious consequences of COVID-19, including hospitalization and death. It is authorized for individuals aged 12 and older. The approval comes a week after the FDA authorized updated mRNA vaccines from Moderna and Pfizer for the KP.2 variant. The Novavax vaccine offers a protein-based immunization option and is expected to be available in pre-filled syringes across the U.S. in the coming days.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 5 million • 25%
5 million to 10 million • 25%
10 million to 15 million • 25%
More than 15 million • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
